Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 154

1.

Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma.

Ascierto PA, Ferrucci PF, Fisher R, Del Vecchio M, Atkinson V, Schmidt H, Schachter J, Queirolo P, Long GV, Di Giacomo AM, Svane IM, Lotem M, Bar-Sela G, Couture F, Mookerjee B, Ghori R, Ibrahim N, Moreno BH, Ribas A.

Nat Med. 2019 Jun;25(6):941-946. doi: 10.1038/s41591-019-0448-9. Epub 2019 Jun 6.

PMID:
31171878
2.

Effectiveness of dabrafenib in the treatment of patients with BRAF V600-mutated metastatic melanoma in a Named Patient Program.

Martin-Algarra S, Hinshelwood R, Mesnage S, Cebon J, Ferrucci PF, Aglietta M, Neyns B, Chiarion-Sileni V, Lindsay CR, Del Vecchio M, Linardou H, Merelli B, Tonini G, Atkinson V, Freivogel K, Stein D, Dalland L, Lau M, Legenne P, Queirolo P, Millward M.

Melanoma Res. 2019 May 14. doi: 10.1097/CMR.0000000000000608. [Epub ahead of print]

PMID:
31095039
3.

Identification and Management of Immune Checkpoint Inhibitor-Related Myocarditis: Use Troponin Wisely.

Spallarossa P, Tini G, Sarocchi M, Arboscello E, Grossi F, Queirolo P, Zoppoli G, Ameri P.

J Clin Oncol. 2019 May 14:JCO1802464. doi: 10.1200/JCO.18.02464. [Epub ahead of print] No abstract available.

PMID:
31084547
4.

Biomarker results from a phase II study of MEK1/2 inhibitor binimetinib (MEK162) in patients with advanced NRAS- or BRAF-mutated melanoma.

van Herpen CML, Agarwala SS, Hauschild A, Berking C, Beck JT, Schadendorf D, Jansen R, Queirolo P, Ascierto PA, Blank CU, Heinrich MC, Pal RR, Derti A, Antona V, Nauwelaerts H, Zubel A, Dummer R.

Oncotarget. 2019 Mar 5;10(19):1850-1859. doi: 10.18632/oncotarget.26753. eCollection 2019 Mar 5.

5.

An open-label, multicentre safety study of vemurafenib in patients with BRAFV600-mutant metastatic melanoma: final analysis and a validated prognostic scoring system.

Larkin J, Brown MP, Arance AM, Hauschild A, Queirolo P, Vecchio MD, Ascierto PA, Krajsová I, Schachter J, Neyns B, Garbe C, Sileni VC, Mandalà M, Gogas H, Espinosa E, Hospers G, Lorigan P, Nyakas M, Guminski A, Liszkay G, Rutkowski P, Miller W Jr, Donica M, Makrutzki M, Blank C.

Eur J Cancer. 2019 Jan;107:175-185. doi: 10.1016/j.ejca.2018.11.018. Epub 2018 Dec 20.

PMID:
30580112
6.

Comprehensive Study of the Clinical Phenotype of Germline BAP1 Variant-Carrying Families Worldwide.

Walpole S, Pritchard AL, Cebulla CM, Pilarski R, Stautberg M, Davidorf FH, de la Fouchardière A, Cabaret O, Golmard L, Stoppa-Lyonnet D, Garfield E, Njauw CN, Cheung M, Turunen JA, Repo P, Järvinen RS, van Doorn R, Jager MJ, Luyten GPM, Marinkovic M, Chau C, Potrony M, Höiom V, Helgadottir H, Pastorino L, Bruno W, Andreotti V, Dalmasso B, Ciccarese G, Queirolo P, Mastracci L, Wadt K, Kiilgaard JF, Speicher MR, van Poppelen N, Kilic E, Al-Jamal RT, Dianzani I, Betti M, Bergmann C, Santagata S, Dahiya S, Taibjee S, Burke J, Poplawski N, O'Shea SJ, Newton-Bishop J, Adlard J, Adams DJ, Lane AM, Kim I, Klebe S, Racher H, Harbour JW, Nickerson ML, Murali R, Palmer JM, Howlie M, Symmons J, Hamilton H, Warrier S, Glasson W, Johansson P, Robles-Espinoza CD, Ossio R, de Klein A, Puig S, Ghiorzo P, Nielsen M, Kivelä TT, Tsao H, Testa JR, Gerami P, Stern MH, Paillerets BB, Abdel-Rahman MH, Hayward NK.

J Natl Cancer Inst. 2018 Dec 1;110(12):1328-1341. doi: 10.1093/jnci/djy171.

PMID:
30517737
7.

Soluble CTLA-4 as a favorable predictive biomarker in metastatic melanoma patients treated with ipilimumab: an Italian melanoma intergroup study.

Pistillo MP, Fontana V, Morabito A, Dozin B, Laurent S, Carosio R, Banelli B, Ferrero F, Spano L, Tanda E, Ferrucci PF, Martinoli C, Cocorocchio E, Guida M, Tommasi S, De Galitiis F, Pagani E, Antonini Cappellini GC, Marchetti P, Quaglino P, Fava P, Osella-Abate S, Ascierto PA, Capone M, Simeone E, Romani M, Spagnolo F, Queirolo P; Italian Melanoma Intergroup (IMI).

Cancer Immunol Immunother. 2019 Jan;68(1):97-107. doi: 10.1007/s00262-018-2258-1. Epub 2018 Oct 11.

PMID:
30311027
8.

Efficacy of novel immunotherapy regimens in patients with metastatic melanoma with germline CDKN2A mutations.

Helgadottir H, Ghiorzo P, van Doorn R, Puig S, Levin M, Kefford R, Lauss M, Queirolo P, Pastorino L, Kapiteijn E, Potrony M, Carrera C, Olsson H, Höiom V, Jönsson G.

J Med Genet. 2018 Oct 5. pii: jmedgenet-2018-105610. doi: 10.1136/jmedgenet-2018-105610. [Epub ahead of print]

9.

CDKN2A germline mutations are not associated with poor survival in an Italian cohort of melanoma patients.

Dalmasso B, Pastorino L, Ciccarese G, Andreotti V, Grillo F, Mastracci L, Spagnolo F, Ballestrero A, Queirolo P, Bruno W, Ghiorzo P.

J Am Acad Dermatol. 2019 May;80(5):1263-1271. doi: 10.1016/j.jaad.2018.07.060. Epub 2018 Sep 28.

PMID:
30274933
10.

Correction: Combining molecular and immunohistochemical analyses of key drivers in primary melanomas: interplay between germline and somatic variations.

Bruno W, Martinuzzi C, Dalmasso B, Andreotti V, Pastorino L, Cabiddu F, Gualco M, Spagnolo F, Ballestrero A, Queirolo P, Grillo F, Mastracci L, Ghiorzo P.

Oncotarget. 2018 Jun 19;9(47):28798. doi: 10.18632/oncotarget.25684. eCollection 2018 Jun 19.

11.

Vitamin D in melanoma: Controversies and potential role in combination with immune check-point inhibitors.

Stucci LS, D'Oronzo S, Tucci M, Macerollo A, Ribero S, Spagnolo F, Marra E, Picasso V, Orgiano L, Marconcini R, De Rosa F, Di Guardo L, Galli G, Gandini S, Palmirotta R, Palmieri G, Queirolo P, Silvestris F; Italian Melanoma Intergroup (IMI).

Cancer Treat Rev. 2018 Sep;69:21-28. doi: 10.1016/j.ctrv.2018.05.016. Epub 2018 May 31. Review.

PMID:
29864718
12.

CTLA-4 gene variant -1661A>G may predict the onset of endocrine adverse events in metastatic melanoma patients treated with ipilimumab.

Queirolo P, Dozin B, Morabito A, Banelli B, Carosio R, Fontana V, Ferrucci PF, Martinoli C, Cocorocchio E, Ascierto PA, Madonna G, Simeone E, De Galitiis F, Antonini Cappellini GC, Marchetti P, Guida M, Tommasi S, Ghilardi L, Merelli B, Fava P, Osella-Abate S, Guidoboni M, Romani M, Ferone D, Spagnolo F, Pistillo MP; Italian Melanoma Intergroup (IMI).

Eur J Cancer. 2018 Jul;97:59-61. doi: 10.1016/j.ejca.2018.04.005. Epub 2018 May 7. No abstract available.

PMID:
29743138
13.

Effect of Age on Melanoma Risk, Prognosis and Treatment Response.

Ribero S, Stucci LS, Marra E, Marconcini R, Spagnolo F, Orgiano L, Picasso V, Queirolo P, Palmieri G, Quaglino P, Bataille V.

Acta Derm Venereol. 2018 Jul 11;98(7):624-629. doi: 10.2340/00015555-2944. Review.

14.

Current status and perspectives in immunotherapy for metastatic melanoma.

Marconcini R, Spagnolo F, Stucci LS, Ribero S, Marra E, Rosa F, Picasso V, Di Guardo L, Cimminiello C, Cavalieri S, Orgiano L, Tanda E, Spano L, Falcone A, Queirolo P; Italian Melanoma Intergroup (IMI).

Oncotarget. 2018 Jan 3;9(15):12452-12470. doi: 10.18632/oncotarget.23746. eCollection 2018 Feb 23. Review.

15.

Corrigendum: Association of CTLA-4 Gene Variants with Response to Therapy and Long-term Survival in Metastatic Melanoma Patients Treated with Ipilimumab: An Italian Melanoma Intergroup Study.

Queirolo P, Dozin B, Morabito A, Banelli B, Piccioli P, Fava C, Leo C, Carosio R, Laurent S, Fontana V, Ferrucci PF, Martinoli C, Cocorocchio E, Battaglia A, Ascierto PA, Capone M, Simeone E, De Galitiis F, Pagani E, Antonini Cappellini GC, Marchetti P, Guida M, Tommasi S, Mandalà M, Merelli B, Quaglino P, Fava P, Guidoboni M, Romani M, Spagnolo F, Pistillo MP.

Front Immunol. 2018 Mar 2;9:403. doi: 10.3389/fimmu.2018.00403. eCollection 2018.

16.

Combining molecular and immunohistochemical analyses of key drivers in primary melanomas: interplay between germline and somatic variations.

Bruno W, Martinuzzi C, Dalmasso B, Andreotti V, Pastorino L, Cabiddu F, Gualco M, Spagnolo F, Ballestrero A, Queirolo P, Grillo F, Mastracci L, Ghiorzo P.

Oncotarget. 2017 Dec 14;9(5):5691-5702. doi: 10.18632/oncotarget.23204. eCollection 2018 Jan 19. Erratum in: Oncotarget. 2018 Jun 19;9(47):28798.

17.

Correction to: Clinicopathological predictors of recurrence in nodular and superficial spreading cutaneous melanoma: a multivariate analysis of 214 cases.

Pizzichetta MA, Massi D, Mandalà M, Queirolo P, Stanganelli I, De Giorgi V, Ghigliotti G, Cavicchini S, Quaglino P, Corradin MT, Rubegni P, Alaibac M, Astorino S, Ayala F, Magi S, Mazzoni L, Manganoni MA, Talamini R, Serraino D, Palmieri G; Italian Melanoma Intergroup (IMI).

J Transl Med. 2018 Feb 20;16(1):33. doi: 10.1186/s12967-018-1408-8.

18.

[Pembrolizumab for the treatment of melanoma: updates and perspectives.]

Chiarion Sileni V, Mandalà M, Queirolo P.

Recenti Prog Med. 2017 Dec;108(12):528-531. doi: 10.1701/2829.28585. Review. Italian.

PMID:
29297903
19.

Clinicopathological predictors of recurrence in nodular and superficial spreading cutaneous melanoma: a multivariate analysis of 214 cases.

Pizzichetta MA, Massi D, Mandalà M, Queirolo P, Stanganelli I, De Giorgi V, Ghigliotti G, Cavicchini S, Quaglino P, Corradin MT, Rubegni P, Alaibac M, Astorino S, Ayala F, Magi S, Mazzoni L, Manganoni MA, Talamini R, Serraino D, Palmieri G; Italian Melanoma Intergroup (IMI).

J Transl Med. 2017 Nov 7;15(1):227. doi: 10.1186/s12967-017-1332-3. Erratum in: J Transl Med. 2018 Feb 20;16(1):33.

20.

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma.

Weber J, Mandala M, Del Vecchio M, Gogas HJ, Arance AM, Cowey CL, Dalle S, Schenker M, Chiarion-Sileni V, Marquez-Rodas I, Grob JJ, Butler MO, Middleton MR, Maio M, Atkinson V, Queirolo P, Gonzalez R, Kudchadkar RR, Smylie M, Meyer N, Mortier L, Atkins MB, Long GV, Bhatia S, Lebbé C, Rutkowski P, Yokota K, Yamazaki N, Kim TM, de Pril V, Sabater J, Qureshi A, Larkin J, Ascierto PA; CheckMate 238 Collaborators.

N Engl J Med. 2017 Nov 9;377(19):1824-1835. doi: 10.1056/NEJMoa1709030. Epub 2017 Sep 10.

21.

Binimetinib for the treatment of NRAS-mutant melanoma.

Queirolo P, Spagnolo F.

Expert Rev Anticancer Ther. 2017 Nov;17(11):985-990. doi: 10.1080/14737140.2017.1374177. Epub 2017 Sep 8. Review.

PMID:
28851243
22.

TP63 mutations are frequent in cutaneous melanoma, support UV etiology, but their role in melanomagenesis is unclear.

Monti P, Ghiorzo P, Menichini P, Foggetti G, Queirolo P, Izzotti A, Fronza G.

Oncol Rep. 2017 Oct;38(4):1985-1994. doi: 10.3892/or.2017.5903. Epub 2017 Aug 14.

23.

Atypical responses in patients with advanced melanoma, lung cancer, renal-cell carcinoma and other solid tumors treated with anti-PD-1 drugs: A systematic review.

Queirolo P, Spagnolo F.

Cancer Treat Rev. 2017 Sep;59:71-78. doi: 10.1016/j.ctrv.2017.07.002. Epub 2017 Jul 19. Review.

PMID:
28756306
24.

Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAFV600 mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders' analysis.

Blank CU, Larkin J, Arance AM, Hauschild A, Queirolo P, Del Vecchio M, Ascierto PA, Krajsova I, Schachter J, Neyns B, Garbe C, Chiarion Sileni V, Mandalà M, Gogas H, Espinosa E, Hospers GAP, Miller WH Jr, Robson S, Makrutzki M, Antic V, Brown MP.

Eur J Cancer. 2017 Jul;79:176-184. doi: 10.1016/j.ejca.2017.04.007. Epub 2017 May 11.

PMID:
28501764
25.

Association of CTLA-4 Gene Variants with Response to Therapy and Long-term Survival in Metastatic Melanoma Patients Treated with Ipilimumab: An Italian Melanoma Intergroup Study.

Queirolo P, Dozin B, Morabito A, Banelli B, Piccioli P, Fava C, Leo C, Carosio R, Laurent S, Fontana V, Ferrucci PF, Martinoli C, Cocorocchio E, Battaglia A, Ascierto PA, Capone M, Simeone E, De Galitiis F, Pagani E, Antonini Cappellini GC, Marchetti P, Guida M, Tommasi S, Mandalà M, Merelli B, Quaglino P, Fava P, Guidoboni M, Romani M, Spagnolo F, Pistillo MP.

Front Immunol. 2017 Apr 12;8:386. doi: 10.3389/fimmu.2017.00386. eCollection 2017. Erratum in: Front Immunol. 2018 Mar 02;9:403.

26.

Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab.

Ferrucci PF, Ascierto PA, Pigozzo J, Del Vecchio M, Maio M, Antonini Cappellini GC, Guidoboni M, Queirolo P, Savoia P, Mandalà M, Simeone E, Valpione S, Altomonte M, Spagnolo F, Cocorocchio E, Gandini S, Giannarelli D, Martinoli C.

Ann Oncol. 2018 Feb 1;29(2):524. doi: 10.1093/annonc/mdx059. No abstract available.

PMID:
28379318
27.

Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial.

Guo J, Carvajal RD, Dummer R, Hauschild A, Daud A, Bastian BC, Markovic SN, Queirolo P, Arance A, Berking C, Camargo V, Herchenhorn D, Petrella TM, Schadendorf D, Sharfman W, Testori A, Novick S, Hertle S, Nourry C, Chen Q, Hodi FS.

Ann Oncol. 2017 Jun 1;28(6):1380-1387. doi: 10.1093/annonc/mdx079.

28.

BRAF plus MEK-targeted drugs: a new standard of treatment for BRAF-mutant advanced melanoma.

Queirolo P, Spagnolo F.

Cancer Metastasis Rev. 2017 Mar;36(1):35-42. doi: 10.1007/s10555-017-9660-6. Review.

PMID:
28299583
29.

Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial.

Dummer R, Schadendorf D, Ascierto PA, Arance A, Dutriaux C, Di Giacomo AM, Rutkowski P, Del Vecchio M, Gutzmer R, Mandala M, Thomas L, Demidov L, Garbe C, Hogg D, Liszkay G, Queirolo P, Wasserman E, Ford J, Weill M, Sirulnik LA, Jehl V, Bozón V, Long GV, Flaherty K.

Lancet Oncol. 2017 Apr;18(4):435-445. doi: 10.1016/S1470-2045(17)30180-8. Epub 2017 Mar 9.

PMID:
28284557
30.

Identification, genetic testing, and management of hereditary melanoma.

Leachman SA, Lucero OM, Sampson JE, Cassidy P, Bruno W, Queirolo P, Ghiorzo P.

Cancer Metastasis Rev. 2017 Mar;36(1):77-90. doi: 10.1007/s10555-017-9661-5.

31.

Metastatic melanoma: how research can modify the course of a disease.

Queirolo P, Pfeffer U.

Cancer Metastasis Rev. 2017 Mar;36(1):3-5. doi: 10.1007/s10555-017-9664-2. No abstract available.

PMID:
28197746
32.

Heterogeneity and frequency of BRAF mutations in primary melanoma: Comparison between molecular methods and immunohistochemistry.

Bruno W, Martinuzzi C, Andreotti V, Pastorino L, Spagnolo F, Dalmasso B, Cabiddu F, Gualco M, Ballestrero A, Bianchi-Scarrà G, Queirolo P, Grillo F, Mastracci L, Ghiorzo P; Italian Melanoma Intergroup (IMI).

Oncotarget. 2017 Jan 31;8(5):8069-8082. doi: 10.18632/oncotarget.14094.

33.

Mitotic rate correlates with sentinel lymph node status and outcome in cutaneous melanoma greater than 1 millimeter in thickness: A multi-institutional study of 1524 cases.

Mandalà M, Galli F, Cattaneo L, Merelli B, Rulli E, Ribero S, Quaglino P, De Giorgi V, Pigozzo J, Sileni VC, Chirco A, Ferrucci PF, Occelli M, Imberti G, Piazzalunga D, Massi D, Tondini C, Queirolo P; Italian Melanoma Intergroup.

J Am Acad Dermatol. 2017 Feb;76(2):264-273.e2. doi: 10.1016/j.jaad.2016.08.066. Epub 2016 Nov 12.

PMID:
27847125
34.

Safety and immunogenicity of the PRAME cancer immunotherapeutic in metastatic melanoma: results of a phase I dose escalation study.

Gutzmer R, Rivoltini L, Levchenko E, Testori A, Utikal J, Ascierto PA, Demidov L, Grob JJ, Ridolfi R, Schadendorf D, Queirolo P, Santoro A, Loquai C, Dreno B, Hauschild A, Schultz E, Lesimple TP, Vanhoutte N, Salaun B, Gillet M, Jarnjak S, De Sousa Alves PM, Louahed J, Brichard VG, Lehmann FF.

ESMO Open. 2016 Aug 8;1(4):e000068. eCollection 2016.

35.

[Management of immune-related adverse events during treatment with immune checkpoint inhibitors].

Queirolo P, Spagnolo F.

Recenti Prog Med. 2016 Aug;107(8):407-13. doi: 10.1701/2332.25060. Italian.

PMID:
27571555
36.

Cytokines can counteract the inhibitory effect of MEK-i on NK-cell function.

Manzini C, Venè R, Cossu I, Gualco M, Zupo S, Dono M, Spagnolo F, Queirolo P, Moretta L, Mingari MC, Pietra G.

Oncotarget. 2016 Sep 20;7(38):60858-60871. doi: 10.18632/oncotarget.11504.

37.

Analysis of the Expression and Single-Nucleotide Variant Frequencies of the Butyrophilin-like 2 Gene in Patients With Uveal Melanoma.

Amaro A, Parodi F, Diedrich K, Angelini G, Götz C, Viaggi S, Maric I, Coviello D, Pistillo MP, Morabito A, Mandalà M, Ghiorzo P, Visconti P, Gualco M, Anselmi L, Puzone R, Lanza F, Mosci C, Raggi F, Bosco MC, Varesio L, Zeschnigk M, Spano L, Queirolo P, Pfeffer U.

JAMA Ophthalmol. 2016 Oct 1;134(10):1125-1133. doi: 10.1001/jamaophthalmol.2016.2691.

PMID:
27532663
38.

Multiple rare variants in high-risk pancreatic cancer-related genes may increase risk for pancreatic cancer in a subset of patients with and without germline CDKN2A mutations.

Yang XR, Rotunno M, Xiao Y, Ingvar C, Helgadottir H, Pastorino L, van Doorn R, Bennett H, Graham C, Sampson JN, Malasky M, Vogt A, Zhu B, Bianchi-Scarra G, Bruno W, Queirolo P, Fornarini G, Hansson J, Tuominen R, Burdett L, Hicks B, Hutchinson A, Jones K, Yeager M, Chanock SJ, Landi MT, Höiom V, Olsson H, Gruis N, Ghiorzo P, Tucker MA, Goldstein AM.

Hum Genet. 2016 Nov;135(11):1241-1249. Epub 2016 Jul 23.

39.

Combined vemurafenib and fotemustine in patients with BRAF V600 melanoma progressing on vemurafenib.

Queirolo P, Spagnolo F, Picasso V, Spano L, Tanda E, Fontana V, Giorello L, Merlo DF, Simeone E, Grimaldi AM, Curvietto M, Del Vecchio M, Bruzzi P, Ascierto PA.

Oncotarget. 2016 Jul 13;9(15):12408-12417. doi: 10.18632/oncotarget.10589. eCollection 2018 Feb 23.

40.

Sun exposure and melanoma prognostic factors.

Gandini S, Montella M, Ayala F, Benedetto L, Rossi CR, Vecchiato A, Corradin MT, DE Giorgi V, Queirolo P, Zannetti G, Giudice G, Borroni G, Forcignanò R, Peris K, Tosti G, Testori A, Trevisan G, Spagnolo F, Ascierto PA; CLINICAL NATIONAL MELANOMA REGISTRY GROUP.

Oncol Lett. 2016 Apr;11(4):2706-2714. Epub 2016 Mar 1.

41.

Update on Metastatic Uveal Melanoma: Progress and Challenges.

Spagnolo F, Picasso V, Spano L, Tanda E, Venzano C, Queirolo P.

BioDrugs. 2016 Jun;30(3):161-72. doi: 10.1007/s40259-016-0167-4. Review.

PMID:
27000042
42.

Survival of patients with metastatic melanoma and brain metastases in the era of MAP-kinase inhibitors and immunologic checkpoint blockade antibodies: A systematic review.

Spagnolo F, Picasso V, Lambertini M, Ottaviano V, Dozin B, Queirolo P.

Cancer Treat Rev. 2016 Apr;45:38-45. doi: 10.1016/j.ctrv.2016.03.003. Epub 2016 Mar 8. Review.

PMID:
26975020
43.

Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab.

Ferrucci PF, Ascierto PA, Pigozzo J, Del Vecchio M, Maio M, Antonini Cappellini GC, Guidoboni M, Queirolo P, Savoia P, Mandalà M, Simeone E, Valpione S, Altomonte M, Spagnolo F, Cocorocchio E, Gandini S, Giannarelli D, Martinoli C.

Ann Oncol. 2016 Apr;27(4):732-8. doi: 10.1093/annonc/mdw016. Epub 2016 Jan 22. Erratum in: Ann Oncol. 2018 Feb 1;29(2):524.

PMID:
26802161
44.

[Immunotherapy in the treatment of advanced or metastatic melanoma: nivolumab from phase I studies to approvement by European Medicines Agency].

Queirolo P, Tanda ET.

Recenti Prog Med. 2015 Dec;106(12):608-17. doi: 10.1701/2094.22650. Review. Italian.

PMID:
26780070
45.

Multiple primary melanomas (MPMs) and criteria for genetic assessment: MultiMEL, a multicenter study of the Italian Melanoma Intergroup.

Bruno W, Pastorino L, Ghiorzo P, Andreotti V, Martinuzzi C, Menin C, Elefanti L, Stagni C, Vecchiato A, Rodolfo M, Maurichi A, Manoukian S, De Giorgi V, Savarese I, Gensini F, Borgognoni L, Testori A, Spadola G, Mandalà M, Imberti G, Savoia P, Astrua C, Ronco AM, Farnetti A, Tibiletti MG, Lombardo M, Palmieri G, Ayala F, Ascierto P, Ghigliotti G, Muggianu M, Spagnolo F, Picasso V, Tanda ET, Queirolo P, Bianchi-Scarrà G.

J Am Acad Dermatol. 2016 Feb;74(2):325-32. doi: 10.1016/j.jaad.2015.09.053.

PMID:
26775776
46.

The CDKN2A/p16(INK) (4a) 5'UTR sequence and translational regulation: impact of novel variants predisposing to melanoma.

Andreotti V, Bisio A, Bressac-de Paillerets B, Harland M, Cabaret O, Newton-Bishop J, Pastorino L, Bruno W, Bertorelli R, De Sanctis V, Provenzani A, Menin C, Fronza G, Queirolo P, Spitale RC, Bianchi-Scarrà G, Inga A, Ghiorzo P.

Pigment Cell Melanoma Res. 2016 Mar;29(2):210-21. doi: 10.1111/pcmr.12444. Epub 2015 Dec 17.

PMID:
26581427
47.

Potential Role of Soluble c-Met as a New Candidate Biomarker of Metastatic Uveal Melanoma.

Barisione G, Fabbi M, Gino A, Queirolo P, Orgiano L, Spano L, Picasso V, Pfeffer U, Mosci C, Jager MJ, Ferrini S, Gangemi R.

JAMA Ophthalmol. 2015 Sep;133(9):1013-21. doi: 10.1001/jamaophthalmol.2015.1766.

PMID:
26068448
48.

Vemurafenib in BRAFV600 mutated metastatic melanoma: a subanalysis of the Italian population of a global safety study.

Del Vecchio M, Ascierto PA, Mandalà M, Sileni VC, Maio M, Di Guardo L, Simeone E, Queirolo P.

Future Oncol. 2015;11(9):1355-62. doi: 10.2217/fon.15.55.

PMID:
25952781
49.

Combined BRAF and MEK inhibition for the treatment of BRAF-mutated metastatic melanoma.

Queirolo P, Picasso V, Spagnolo F.

Cancer Treat Rev. 2015 Jun;41(6):519-26. doi: 10.1016/j.ctrv.2015.04.010. Epub 2015 Apr 29. Review.

PMID:
25944484
50.

BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.

Spagnolo F, Ghiorzo P, Orgiano L, Pastorino L, Picasso V, Tornari E, Ottaviano V, Queirolo P.

Onco Targets Ther. 2015 Jan 16;8:157-68. doi: 10.2147/OTT.S39096. eCollection 2015. Review.

Supplemental Content

Loading ...
Support Center